Canadian Duloxetine (Yentreve™, Eli Lilly/Boeh-ringer Ingelheim), has been granted marketing approval in the European Union for the treatment of moderate-to-severe stress urinary incontinence. Patients with this condition experience the accidental leakage of urine during physical activity.
Although stress urinary incontinence is common, it is not considered “normal” at any age. Risk factors include obesity, childbirth, chronic coughing, and constipation.
The drug is currently being evaluated by the FDA, which issued an approvable letter in August 2003. Approval from the agency is expected in 2005.
Approximately 15 million American adult women are affected by stress urinary incontinence.